EU Attack On Drug IP Practices Presents Challenges

Law360, New York (December 1, 2008, 12:00 AM EST) -- The European Commission's report last week accusing major drug companies of working to delay or block the sale of generic versions of their medicines presents a number of challenges both for drugmakers and the commission, competition and intellectual property lawyers say.

The report, which consists of the preliminary findings of an investigation begun in January, criticized several widespread practices in the pharmaceutical industry, such as filing multiple patent applications for the same drug and settlement deals that require generics makers to stay out of the market...
To view the full article, register now.